FORCE Communications-Powered by Petauri™

This is the good stuff! There’s nothing better than joining one’s teammates to learn, share, and get to know each other better. Last week, we held our FORCE Communications-Powered by Petauri™ all-company meeting in Indianapolis, where coworkers from across the country met for 2 days of targeted learning, socializing, and celebrating. One highlight was hearing from a client panel about their experiences and expectations—and a bit of crystal-ball prediction of our industry’s future. Representatives from medical affairs, marketing, and KOL engagement teams graciously shared their expertise and perspectives to help us bring science to life for our clients today and for many years to come. At FORCE, we know that our culture is special. Events like this are a terrific reminder of just how special it is. #medcomms #ourcompany #science #patients #life #culture

The 84th Scientific Sessions of the American Diabetes Association are taking place June 21-24 in Orlando! FORCE is excited to attend, learning about the newest diabetes research findings and networking with industry colleagues.  The number of Americans diagnosed with diabetes is increasing. Prevalence was estimated at 10.3% from 2001 to 2004 and climbed to 13.2% between 2017 and 2020. The total economic burden was estimated at $412.9 billion in 2022. Researchers predict that both figures will continue to increase; thus, effective disease management is critical to the well-being of Americans. In 2023, Eli Lilly and Company and Novo Nordisk both announced that their insulin copay maximums would be capped at $35 per month and were joined by Sanofi in early 2024. This means that most Americans now have access to lower-cost insulin to ease their financial burden.  New treatments such as glucagon-like peptide 1, or GLP-1, and/or gastric inhibitory polypeptide, or GIP, agonists have been revolutionary in treating type 2 diabetes, which shows that continued research into diabetes and related diseases such as obesity still has a large role in further advancing patient care. In March, the FDA approved the first treatment for metabolic-associated steatohepatitis, or MASH, a fatty liver disease that is estimated to affect up to 25% of the global population (and has high overlap with type 2 diabetes and obesity populations). Conferences such as these scientific sessions are critical in sharing important research findings in the field, and we are grateful to be able to enter with open ears.  Will you be there? Let’s chat about what excites you! #diabetes #medcomms #science #obesity #patients 

We are celebrating #MedCommsDay and all of those who work tirelessly to bring science to life. Science moves fast. Patient care can be very complex. @FORCE Communications Powered by Petauri is proud to partner with pharma, biotech and medical device companies to bring transformative science and technology to healthcare providers and patients. #science #medcomms #patientsfirst #innovation  

Yes, science sure does move fast! The presenters and exhibitors proved this once again at the American Society of Clinical Oncology 2024 #ASCO2024 Annual Meeting! We hope your time in Chicago was filled with new information, relationship development and inspiration. Here at FORCE, we look forward to soaking in all of the new science and technology that was shared to enhance the support we provide our clients. #science #patientsfirst #oncology #medcomm 

Thank you to all the presenters at Digestive Disease Week 2024 in Washington, DC! FORCE has enjoyed following along with the data disclosures, and we look forward to reading more about the conference. Were you there? Share with us what you learned!  

The Digestive Disease Week (DDW) 2024 meeting is May 18-21 in Washington, DC, and FORCE can’t wait to follow along! DDW is a premier meeting for professionals working in gastroenterology, hepatology, gastrointestinal (GI) endoscopy, GI surgery, and related fields. With expertise in these areas, FORCE understands the importance of meetings like this to communicate findings from medical and industry professionals across the world.  2023 was a big year in gastroenterology. Various professional groups released new or updated guidelines on diagnosing and managing conditions including gastroesophageal reflux disease (GERD), liver disease and failure, and intestinal bowel disease. Notably, several of these societies combined to issue a statement in response to reported concerns about a link between the use of glucagon-like peptide 1 (GLP-1) inhibitors and sedation during endoscopies. The statement acknowledged these concerns but noted that more data are needed to understand the risks and implications of these complications and encouraged partnership between anesthesiologists, endocrinologists, and industry to gather those data.  2023 also saw several launches in endocrinology. Of 55 novel drugs approved by the FDA, 4 were related to gastroenterology and hepatology. Two of these approvals, Velsipity™ (etrasimod) and Omvoh™ (mirikizumab-mrkz), entered into the ulcerative colitis treatment landscape, joining an already-crowded field that includes aminosalicylates, corticosteroids, immunosuppressants, biologics, and Janus kinase inhibitors (JAKis). The first new treatment for GERD, Voquezna™ (vonoprazan), in decades was also introduced to address unmet patient needs. Are you going to be attending or presenting at DDW 2024? Let us know! We’d love to connect and talk more about our shared interests and see how we can partner together. 

FORCE Recognizes World Lupus Day May is Lupus Awareness Month, and May 10 is World Lupus Day. Often referred to as “the cruel mystery,” lupus is a chronic autoimmune disease that can affect many parts of the body and is difficult to diagnose because symptoms vary from case to case.  There is no single test to diagnose lupus, and the average time to diagnosis from the onset of symptoms is 6 years. Symptoms may include pain or swelling in the joints, a butterfly-shaped rash on the face, chest pain, hair loss, blood clotting, extreme fatigue, damage to organs and tissues, and more.  Lupus can be disabling and potentially fatal, and there is currently no cure. There are only 3 therapies approved by the FDA to treat lupus, and patients take on average 8 medications to manage their condition.  Lupus affects 1.5 million Americans, and 90% of lupus cases are seen in women. Lupus is ranked the fifth cause of death among Black and Hispanic women 15-24 years of age. There is a great need for lupus awareness and treatment options, and FORCE welcomes collaboration that works to improve the lives of patients.  

#AAN2024 was exceptional this year! So much new science and information sharing. Patients and clinicians should be optimistic about advancements in diagnosis, treatment, and monitoring. At FORCE Communications, we’re here for it and are eager to get back to work with our biopharma clients to bring education and innovation to the HCP community.  How can we help you? Throw a challenge our way. #AAN2024 #neurology #brainhealth #medcomms 

The 2024 AAN Annual Meeting is off and running and definitely not disappointing! Inspiration is everywhere. Artificial intelligence, health equity impact on brain health, and Alzheimer disease sessions were particularly interesting. What has piqued your interest thus far? #AAN2024 #neurology #brainhealth #medcomms

Hello, Denver! There’s been so much buzz around neurology in recent years. Because FORCE has deep neuro experience, AAN 2024 is especially fascinating to us as we support clients and fuel our passion for Bringing science to life. From migraine to movement disorders to memory loss conditions and more, there’s so much new and exciting science to explore. Top experts from academia, clinical practice, government, and advocacy groups will be sharing a wide array of data and perspectives in the complex arena of brain health. Will you be here? #AAN2024 #neurology #brainhealth #medcomms